Smoking Prevalence and Cessation in Skin Cancer Survivors
Dermatology · 2026
DOI: 10.1159/000550995 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology, 2026. Verfasst von Courtney A Smith und 3 weiteren Autor:innen. Beteiligte Einrichtung: David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Cancer Survivors, Skin Neoplasms, Smoking, Smoking Cessation.
Abstract (Originalsprache)
Introduction
Smoking is associated with worse skin cancer outcomes yet smoking cessation after skin cancer diagnosis remains poorly characterized. This study aimed to examine and compare prevalences of smoking and cessation among skin cancer and internal cancer survivors using nationally representative data.
Methods
This survey-weighted analysis included 2003-2018 National Health and Nutrition Examination Survey data from adults (age 20+) with self-reported cancer history (skin cancers only or internal cancers only). Skin cancer survivors were categorized as those who had non-melanoma skin cancer (NMSC) only or any melanoma. Smoking cessation after first cancer diagnosis was the primary outcome, with smoking status confirmed using serum cotinine. Prevalence outcomes were age-standardized using the direct method and compared by cancer type using age-adjusted logistic regression.
Results
Among 3,711 cancer survivors, 1,098 (29.6%) had skin cancer exclusively. Age-standardized smoking prevalence at cancer diagnosis did not differ by cancer type and was 29.7% (22.8%–36.6%) among skin cancer survivors and 42.3% (37.9%–46.7%) among internal cancer survivors. Among those who smoked at diagnosis, age-standardized post-diagnosis cessation prevalences were low and did not differ between survivors of skin cancers and internal cancers, with 18.1% (12.5%–23.6%) for skin cancer survivors, 20.6% (10.7%–30.5%) for NMSC-only survivors, 11.9% (4.07%–19.6%) for melanoma survivors, and 18.7% (13.9%–23.4%) for internal cancer survivors.
Conclusion
Smoking at skin cancer diagnosis was common with low cessation prevalence across all skin cancer types, highlighting opportunities for dermatologists and clinic staff to implement targeted smoking cessation interventions for skin cancer survivors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
- Augusta University/University of Georgia Medical Partnership, Athens, Georgia, USA.
- Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
- Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia, USA, howa.yeung@emory.edu.
Zitieren
APA
Smith, C. A., Cheng, A., Escoffery, C., & Yeung, H. (2026). Smoking Prevalence and Cessation in Skin Cancer Survivors. Dermatology. https://doi.org/10.1159/000550995
Vancouver
Smith CA, Cheng A, Escoffery C, Yeung H. Smoking Prevalence and Cessation in Skin Cancer Survivors. Dermatology. 2026. doi:10.1159/000550995
BibTeX
@article{Smith2026,
author = {Smith, Courtney A and Cheng, Andrew and Escoffery, Cam and Yeung, Howa},
title = {Smoking Prevalence and Cessation in Skin Cancer Survivors},
journal = {Dermatology},
year = {2026},
doi = {10.1159/000550995}
}
EUVIMED